Semaglutide and Ozempic Dosing: The UK Picture Explained

Ozempic and Wegovy both contain semaglutide, so why are the doses different?

Semaglutide works by activating GLP-1 receptors that influence appetite, blood-sugar regulation and the rate at which the stomach empties. The same biological mechanism underlies both Ozempic and Wegovy, which is why the two products are so often conflated. The difference lies in what each has been studied and approved for. Ozempic was developed and licensed as a treatment for type 2 diabetes, with dosing (0.25mg starter, rising to 0.5mg, then 1mg, and up to 2mg) calibrated around blood-sugar control in people with diabetes. Wegovy was studied specifically for weight management in adults with obesity or overweight, and its dose ceiling is higher: the standard maintenance dose is 2.4mg once weekly, and since early 2026 the MHRA has approved a 7.2mg option as well.

The higher ceiling in Wegovy reflects the fact that greater appetite suppression tends to require a stronger signal. That additional potency also comes with a higher rate of gastrointestinal side effects if the dose is increased too quickly, which is precisely why both products use a slow titration approach. You can read more about how the semaglutide dosing schedule is structured and what the titration steps look like in practice. The practical take-home is simple: the brand on the pen determines not just the licence but the dose ceiling and the product information a prescriber and pharmacist rely on.

For anyone exploring semaglutide for weight loss, the clinically and legally appropriate product in the UK is Wegovy, not Ozempic. A prescriber working within the licensed framework will not prescribe Ozempic off-label for weight management when Wegovy exists specifically for that indication, and UK pharmacies should not dispense it that way either. The relationship between Wegovy and Ozempic is one our team is asked about regularly.

What does the Ozempic dosing schedule actually look like?

Ozempic is administered as a once-weekly subcutaneous injection, typically into the abdomen, thigh or upper arm. The starting dose is 0.25mg weekly for four weeks. This isn't a therapeutic dose, it exists so the body can adjust to the medicine before the pharmacologically active level kicks in. After four weeks the dose moves to 0.5mg, which is the first true treatment dose. Depending on how blood-sugar control responds and how well the medicine is tolerated, a prescriber may increase to 1mg and then to the maximum 2mg.

The titration schedule is determined by the prescriber, not by the patient. Missing doses, delaying titration or trying to accelerate it are all matters to discuss with whoever issued the prescription. The Patient Information Leaflet and the NHS semaglutide medicines page carry the full practical guidance on what to do if a dose is missed or if side effects become difficult to manage. It is also worth noting that Ozempic and Wegovy, despite sharing an active ingredient, are not interchangeable pens, the cartridge, needle system and dosing mechanism differ between them.

People who have read about higher doses used in weight-loss trials and wonder whether their Ozempic prescription could be titrated to match are asking the wrong product. Ozempic's approved maximum in the UK is 2mg; going higher is outside the product's licence. For weight management at those higher doses, Wegovy is the licensed route. The use of semaglutide for weight loss has its own evidence base and its own licensed product.

Is Ozempic ever the right choice for someone trying to lose weight?

Directly: no, not as a licensed weight-loss treatment in the UK. The MHRA's guidance is plain, Ozempic is not licensed for weight management, and it is not assessed for use in people whose sole aim is weight loss without a diabetes diagnosis. Some people will have type 2 diabetes and obesity, and for them Ozempic may be the appropriate choice for managing their blood sugar; any weight reduction that follows is a secondary benefit, not the licensed aim.

This distinction matters because it affects everything from the dose ceiling to the clinical monitoring framework and the information a prescriber uses when reviewing progress. The medicine assessed for weight management (studied in large trials, scrutinised by NICE, and approved by the MHRA specifically for that purpose) is Wegovy. NICE's appraisal of semaglutide for weight management, published as TA875, covers Wegovy, not Ozempic. That appraisal recommends semaglutide for weight loss only within a specialist service and for a maximum of two years, with specific BMI thresholds and the requirement for at least one weight-related condition for those below BMI 35.

For those who do not meet NHS criteria or who face long waiting lists, the private route via a GPhC-registered pharmacy prescribing Wegovy within its licensed framework is the legal alternative. The cost of Wegovy privately varies by dose and provider; what should not vary is the requirement for a genuine clinical assessment before any semaglutide product is prescribed. Our clinical team at nume reviews every consultation personally. If you are ready to find out whether Wegovy suits your situation, you can check your eligibility with our prescribers at no charge.

What about the newer oral semaglutide, does that follow a different dose schedule?

Yes, notably so. The MHRA approved Wegovy tablets in June 2026, making the UK the first country in Europe to licence an oral GLP-1 medicine for weight management. The tablet form uses a co-formulation with an absorption enhancer called SNAC to allow the medicine to cross from the gut into the bloodstream, because semaglutide taken as a plain tablet would be destroyed by stomach acid before it could act.

The dose schedule for Wegovy tablets runs 1.5mg, 4mg, 9mg and 25mg, one tablet daily, with a minimum of one month at each step before moving up. That 25mg maintenance figure looks very different from the 2.4mg used for the weekly injection, but the doses are not directly comparable because oral bioavailability is much lower than subcutaneous injection. The clinical trial evidence (from the OASIS 4 study) showed around 13.6% average weight loss over 64 weeks versus around 2.4% with placebo, with higher reductions among those who adhered fully. The tablet must be taken first thing in the morning on an empty stomach with a small amount of plain water, and nothing else (no food, no coffee, no other medicines) for at least 30 minutes afterward.

Rybelsus, which is also oral semaglutide, uses 3mg, 7mg and 14mg strengths. That product is licensed for type 2 diabetes, not weight loss. The two oral semaglutide products serve different indications, just as Ozempic and Wegovy do in injectable form. To understand more about semaglutide across its various licensed forms, or to explore what Wegovy involves as a treatment, those pages go into the detail each topic deserves.